Auxly Cannabis Group Inc (XLY) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Auxly Cannabis Group Inc C$0.70, price C$3.42, upside -79.6%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Auxly Cannabis Group Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range C$0.1400 – C$3.73 · fair‑value band C$0.3570 – C$0.9010 · the C$3.42 price screens above the C$0.6970 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Auxly Cannabis Group in your weekly email
Every Wednesday you see whether Auxly Cannabis Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Auxly Cannabis Group Inc. operates as a consumer-packaged goods company in the cannabis products market in Canada. The company offers dried and fresh cannabis, plants, seeds, and oils; and edibles, extracts, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names.
Show more
Auxly Cannabis Group Inc. operates as a consumer-packaged goods company in the cannabis products market in Canada. The company offers dried and fresh cannabis, plants, seeds, and oils; and edibles, extracts, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names. It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is headquartered in Toronto, Canada.
Stock analysis
Auxly Cannabis Group Inc (XLY) currently trades at C$3.42, while our model-based Fair Value estimate is C$0.6970, 79.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of C$1.36 per share, and 0 of the 24 models we run sit above the C$3.42 price.
Bear case: the Asset-Based group reads lowest at C$0.0800, and 24 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: C$0.3570 (bear) to C$0.9010 (bull), the price of C$3.42 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Auxly Cannabis Group Inc reported revenue of C$151M in FY2025 versus C$83.8M in FY2021, a compound +15.9%/yr. Reported net income was C$41.9M in FY2025.
Key figures
Market cap C$244M (≈ $171M) · P/E ratio 8.5 · P/S ratio 2.35 · EPS (TTM) C$0.0200 · Net margin 27.6% · Return on equity 21.3% · Return on assets (EBIT) −3.1% · Operating margin 11.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 112% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −80%, XLY screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (C$0.0800 to C$1.38). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear C$0.3570Fair Value C$0.6970Bull C$0.9010
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (C$0.0151 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.92/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+23.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.5%
Start year 2020 (pandemic). Over 10 years: +89.2% a year
Revenue growth 28 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+96.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−115.6% (2020) → 21.6% (2025)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+71.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Canada: IMF forecast 2.1% a year to 2030, 2.6% from 2016 to 2025) that is about +68.0% a year for the price.
Compare Auxly Cannabis Group Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 7/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside−79.1% · Bottom 25%
Profitability
Return on equity (TTM)21.3% · Top 25%
Return on assets7.2% · Top 25%
Net margin (TTM)20.9% · Top 25%
Operating margin (TTM)11.8% · Above median
Growth and dividend
Revenue growth21.7% · Top 25%
Balance sheet
Debt / equity0.23× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)8.5× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 17
FUTURE (revenue growth)100· sector 24
PAST (return on equity)85· sector 27
HEALTH (low debt)89· sector 96
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Auxly Cannabis Group Inc Fair Value". https://www.fairvalue-calculator.com/stock/XLY
Frequently asked questions
Is Auxly Cannabis Group Inc (XLY) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of C$0.6970 versus a price of C$3.42, about −80% upside (overvalued).
What is the fair value of XLY?
Our model-based fair value for Auxly Cannabis Group Inc is C$0.6970 (as of Sep 27, 2026), built from audited fundamentals. The current price: C$3.42.
What is the quality score of XLY?
Auxly Cannabis Group Inc has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Auxly Cannabis Group Inc (XLY)?
Our model-based price target is the fair value of C$0.6970 (as of Sep 27, 2026) from 24 valuation models. Cautious scenario C$0.3570, optimistic scenario C$0.9010. It is a calculation from audited fundamentals, not an analyst target.
What is the Auxly Cannabis Group Inc stock forecast for 2026?
Our models put fair value at C$0.6970, about −80% upside versus a price of C$3.42 (overvalued). Cautious scenario C$0.3570, optimistic scenario C$0.9010. The calculation is refreshed regularly with new filings.
What is the revenue of Auxly Cannabis Group Inc (XLY)?
Auxly Cannabis Group Inc reported trailing-twelve-month revenue of about C$159M (latest available figure, as of Sep 27, 2026).
What growth is priced into Auxly Cannabis Group Inc (XLY)?
For today's price to be fair in a discounted-cash-flow model, Auxly Cannabis Group Inc would have to grow free cash flow by +71.6 % per year for five years (discount rate 13.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +26.5 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of XLY use?
Our models discount Auxly Cannabis Group Inc at 13.1 %: a base by market capitalisation (micro), damped by beta 1.20, country premium for Canada. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Auxly Cannabis Group Inc that is +71.6 % per year a year over ten years, using the same discount rate (13.1 %) and the same formula as our fair value.
How much growth has Auxly Cannabis Group Inc (XLY) delivered so far?
Over the past 5 years revenue at Auxly Cannabis Group Inc grew +26.5 % a year. The price currently implies +71.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Auxly Cannabis Group Inc (XLY) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Auxly Cannabis Group Inc (+71.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Auxly Cannabis Group Inc (XLY)?
The free-cash-flow yield on the price is 0.43 %: that much free cash flow Auxly Cannabis Group Inc produces per unit of market value. When it exceeds the discount rate of our models (13.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Auxly Cannabis Group Inc (XLY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Auxly Cannabis Group Inc it is C$0.6970 per share (as of Sep 27, 2026), against a price of C$3.42. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Auxly Cannabis Group Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, XLY trades above its calculated fair value: price C$3.42, fair value C$0.6970, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of XLY?
No. The price is what the market pays today (C$3.42); the fair value is what the company's own numbers justify (C$0.6970). For Auxly Cannabis Group Inc the two are C$2.72 per share apart. That gap is exactly why we show both numbers side by side.
How much is Auxly Cannabis Group Inc worth?
The market values Auxly Cannabis Group Inc at about C$244M (market capitalisation, as of Sep 27, 2026). Per share that is C$3.42; our models calculate a fair value of C$0.6970 per share.
What do the bullish and bearish scenarios say about XLY?
Our models span a range for Auxly Cannabis Group Inc: cautious scenario C$0.3570, base C$0.6970, optimistic C$0.9010 per share (as of Sep 27, 2026, price C$3.42). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of XLY?
Auxly Cannabis Group Inc trades at a price-to-earnings ratio of 8.5 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of C$0.6970 is built from several models across several years.
How solid is the balance sheet of Auxly Cannabis Group Inc (XLY)?
Balance-sheet figures for Auxly Cannabis Group Inc (as of Sep 27, 2026): return on equity 21.3%, debt of 0.23 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is XLY from its 52-week high?
Auxly Cannabis Group Inc trades at C$3.42, about 8% below its 52-week high of C$3.73 and 112% above the low of C$1.61 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.6970 is for.
Which stocks are comparable to Auxly Cannabis Group Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Auxly Cannabis Group Inc stock attractive at the current price?
The data as of Sep 27, 2026: price C$3.42, calculated fair value C$0.6970 (−80%), Quality Score 59/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of XLY calculated?
We run Auxly Cannabis Group Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of C$0.6970, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Auxly Cannabis Group Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Auxly Cannabis Group Inc (XLY)?
The closing price on Oct 2, 2026 was C$3.42. Our model-based fair value is C$0.6970, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Auxly Cannabis Group Inc right now?
The price sits above even our optimistic bull case (C$0.9010). The favourable scenario is already priced in. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (C$0.3570 to C$0.9010) leaves room in how you read the outcome.
Key figures of Auxly Cannabis Group Inc
How large is the market capitalisation of Auxly Cannabis Group Inc (XLY)?
The market capitalisation of Auxly Cannabis Group Inc is C$244M (≈ $171M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Auxly Cannabis Group Inc (XLY)?
The price-to-sales ratio of Auxly Cannabis Group Inc is 2.35 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Auxly Cannabis Group Inc (XLY)?
Earnings per share at Auxly Cannabis Group Inc are C$0.0200 (price ÷ EPS = P/E 8.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Auxly Cannabis Group Inc (XLY)?
The net margin of Auxly Cannabis Group Inc is 27.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Auxly Cannabis Group Inc (XLY)?
The return on equity (ROE) of Auxly Cannabis Group Inc is 21.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Auxly Cannabis Group Inc (XLY)?
On an EBIT basis the return on assets of Auxly Cannabis Group Inc is −3.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Auxly Cannabis Group Inc (XLY)?
The operating margin of Auxly Cannabis Group Inc is 11.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Auxly Cannabis Group Inc (XLY)?
Revenue at Auxly Cannabis Group Inc is growing +21.7% versus a year earlier (3y avg +17.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Auxly Cannabis Group Inc (XLY)?
Earnings per share at Auxly Cannabis Group Inc are growing −76.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Auxly Cannabis Group Inc (XLY) carry?
The net debt of Auxly Cannabis Group Inc is C$25.1M (fiscal year 2025, ≈ 1.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Auxly Cannabis Group Inc in the live analysis
One click puts Auxly Cannabis Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
